March 25, 2022
Disrupting N-glycan expression on tumor cells enhanced CAR T cell efficacy. Greco et al. treated mice with 2-deoxy-D-glucose (Focus Cat.# 10-2171), a glucose analog, disrupting N-glycan […]
March 23, 2022
The FDA has approved the use of olaparib (Focus Cat.# 10-2154) as adjuvant treatment for patients with BRCA-mutated HER-2 negative high-risk early breast cancer that were […]
March 17, 2022
In a paper just out in Cell, Marco De Giovanni et al. at UCSF demonstrated that 5-hydroxyindoleacetic acid (5-HIAA), a platelet serotonin metabolite, acts as a […]
March 3, 2022
NSD2 (nuclear receptor-binding SET domain-containing 2) is a methyltransferase that specifically targets histone H3 at Lysine 36 (making it a H3K36me2 in chromatin remodeling nomenclature). It […]
March 1, 2022
In a PNAS paper just out Yu and coworkers showed that the small molecule NEDD8-activating enzyme (NAE) inhibitor MLN4924 (pevonedistat, Focus Cat# 10-1311) reduces ischemic brain […]
February 7, 2022
A team at Toronto’s Hospital for Sick Children demonstrated that pharmacological ablation of senescent cells using Navitoclax (ABT-263, Focus Cat#10-3141) caused a rapid increase in neural […]
January 24, 2022
The 2021 Nobel Prize in Medicine was awarded to David Julius and Ardem Patapoutian because of their research on TRPV1 (Transient Receptor Potential Vanilloid 1) and […]
December 2, 2020
The emergence of SARS-CoV-2 has precipitated an unprecedented effort by the scientific community to find and develop potential therapeutics and vaccines for this new virus to […]
August 24, 2020
Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone […]
